John K. Buolamwini

4.8k total citations · 1 hit paper
75 papers, 3.1k citations indexed

About

John K. Buolamwini is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, John K. Buolamwini has authored 75 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Molecular Biology, 30 papers in Oncology and 21 papers in Organic Chemistry. Recurrent topics in John K. Buolamwini's work include Adenosine and Purinergic Signaling (18 papers), Cancer-related Molecular Pathways (14 papers) and HIV/AIDS drug development and treatment (13 papers). John K. Buolamwini is often cited by papers focused on Adenosine and Purinergic Signaling (18 papers), Cancer-related Molecular Pathways (14 papers) and HIV/AIDS drug development and treatment (13 papers). John K. Buolamwini collaborates with scholars based in United States, China and Canada. John K. Buolamwini's co-authors include Shantaram Kamath, Francis Ali‐Osman, Jia-Xi Mao, Gamil R. Antoun, Haregewein Assefa, Shivaputra A. Patil, Tino W. Sanchez, Nouri Neamati, Raymond F. Schinazi and Amol Gupte and has published in prestigious journals such as Journal of Biological Chemistry, Nature Communications and Gastroenterology.

In The Last Decade

John K. Buolamwini

75 papers receiving 3.0k citations

Hit Papers

Molecular Cloning, Charac... 1997 2026 2006 2016 1997 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Molecular Cloning, Characterization, and Expression in Escherichia coli of Full-length cDNAs of Three Human Glutathione S-Transferase Pi Gene Variants
    1997 619 citations John K. Buolamwini et al. Journal of Biological Chemistry profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
John K. Buolamwini United States 29 1.9k 755 728 286 280 75 3.1k
Daniel Zaharevitz United States 32 2.2k 1.2× 1.1k 1.5× 1.2k 1.6× 342 1.2× 181 0.6× 51 4.0k
A. Chaikuad Germany 37 2.9k 1.5× 760 1.0× 784 1.1× 393 1.4× 102 0.4× 123 4.4k
Daniel Martinez Molina Sweden 16 3.1k 1.6× 395 0.5× 605 0.8× 527 1.8× 149 0.5× 20 4.3k
Thomas O’Brien United States 31 2.7k 1.4× 364 0.5× 743 1.0× 341 1.2× 64 0.2× 62 3.6k
Jacqueline Plowman United States 27 1.8k 0.9× 797 1.1× 682 0.9× 149 0.5× 255 0.9× 66 2.9k
Daniel A. Bachovchin United States 34 4.1k 2.2× 1.1k 1.5× 1.0k 1.4× 139 0.5× 175 0.6× 54 5.5k
Fabrizio Giordanetto Sweden 29 2.7k 1.4× 807 1.1× 524 0.7× 789 2.8× 154 0.6× 73 4.1k
Masami Otsuka Japan 29 1.6k 0.8× 1.5k 1.9× 531 0.7× 129 0.5× 236 0.8× 170 3.3k
Haiying Chen United States 31 2.7k 1.4× 670 0.9× 1.0k 1.4× 128 0.4× 185 0.7× 129 4.8k
Rozbeh Jafari Sweden 9 2.6k 1.4× 340 0.5× 527 0.7× 434 1.5× 132 0.5× 25 3.6k

Countries citing papers authored by John K. Buolamwini

Since Specialization
Citations

This map shows the geographic impact of John K. Buolamwini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John K. Buolamwini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John K. Buolamwini more than expected).

Fields of papers citing papers by John K. Buolamwini

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by John K. Buolamwini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John K. Buolamwini. The network helps show where John K. Buolamwini may publish in the future.

Co-authorship network of co-authors of John K. Buolamwini

This figure shows the co-authorship network connecting the top 25 collaborators of John K. Buolamwini. A scholar is included among the top collaborators of John K. Buolamwini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with John K. Buolamwini. John K. Buolamwini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Qin, Jiang‐Jiang, Wei Wang, Xin Li, et al.. (2018). Inhibiting β-Catenin by β-Carboline-Type MDM2 Inhibitor for Pancreatic Cancer Therapy. Frontiers in Pharmacology. 9. 5–5. 21 indexed citations
3.
4.
Wang, Chunmei, Luciana P. Schwab, Meiyun Fan, Tiffany N. Seagroves, & John K. Buolamwini. (2013). Chemoprevention Activity of Dipyridamole in the MMTV-PyMT Transgenic Mouse Model of Breast Cancer. Cancer Prevention Research. 6(5). 437–447. 17 indexed citations
5.
Passer, Brent J., Tooba A. Cheema, Bingsen Zhou, et al.. (2010). Identification of the ENT1 Antagonists Dipyridamole and Dilazep as Amplifiers of Oncolytic Herpes Simplex Virus-1 Replication. Cancer Research. 70(10). 3890–3895. 26 indexed citations
6.
Wang, Hongbo, et al.. (2010). A Small-Molecule Inhibitor of MDMX Activates p53 and Induces Apoptosis. Molecular Cancer Therapeutics. 10(1). 69–79. 100 indexed citations
7.
Hevener, Kirk E., David M. Ball, John K. Buolamwini, & Richard Lee. (2008). Quantitative structure–activity relationship studies on nitrofuranyl anti-tubercular agents. Bioorganic & Medicinal Chemistry. 16(17). 8042–8053. 45 indexed citations
8.
Gupte, Amol & John K. Buolamwini. (2008). Synthesis and biological evaluation of phloridzin analogs as human concentrative nucleoside transporter 3 (hCNT3) inhibitors. Bioorganic & Medicinal Chemistry Letters. 19(3). 917–921. 29 indexed citations
9.
Luo, Wenjing, Jinyi Liu, Jingxia Li, et al.. (2008). Anti-cancer Effects of JKA97 Are Associated with Its Induction of Cell Apoptosis via a Bax-dependent and p53-independent Pathway. Journal of Biological Chemistry. 283(13). 8624–8633. 33 indexed citations
10.
Buolamwini, John K., et al.. (2008). Constrained NBMPR analogue synthesis, pharmacophore mapping and 3D-QSAR modeling of equilibrative nucleoside transporter 1 (ENT1) inhibitory activity. Bioorganic & Medicinal Chemistry. 16(7). 3848–3865. 15 indexed citations
11.
Gupte, Amol & John K. Buolamwini. (2007). Novel C2-purine position analogs of nitrobenzylmercaptopurine riboside as human equilibrative nucleoside transporter 1 inhibitors. Bioorganic & Medicinal Chemistry. 15(24). 7726–7737. 9 indexed citations
12.
Lin, Wenwei & John K. Buolamwini. (2007). Synthesis, Flow Cytometric Evaluation, and Identification of Highly Potent Dipyridamole Analogues as Equilibrative Nucleoside Transporter 1 Inhibitors. Journal of Medicinal Chemistry. 50(16). 3906–3920. 25 indexed citations
13.
Patil, Shivaputra A., Shantaram Kamath, Tino W. Sanchez, et al.. (2006). Synthesis and biological evaluation of novel 5(H)-phenanthridin-6-ones, 5(H)-phenanthridin-6-one diketo acid, and polycyclic aromatic diketo acid analogs as new HIV-1 integrase inhibitors. Bioorganic & Medicinal Chemistry. 15(3). 1212–1228. 96 indexed citations
14.
Adjei, Alex A. & John K. Buolamwini. (2006). Novel anticancer agents : strategies for discovery and clinical testing. Elsevier eBooks. 7 indexed citations
15.
Kamath, Shantaram & John K. Buolamwini. (2006). Targeting EGFR and HER-2 receptor tyrosine kinases for cancer drug discovery and development. Medicinal Research Reviews. 26(5). 569–594. 115 indexed citations
16.
Kamath, Shantaram & John K. Buolamwini. (2005). Asp746 to Glycine Change May have a Greater Influence than Cys751 to Serine Change in Accounting for Ligand Selectivity between EGFR and HER-2 at the ATP Site. Journal of Computer-Aided Molecular Design. 19(5). 287–291. 1 indexed citations
17.
Gupte, Amol, John K. Buolamwini, Vikas Yadav, et al.. (2005). 6-Benzylthioinosine analogues: Promising anti-toxoplasmic agents as inhibitors of the mammalian nucleoside transporter ENT1 (es). Biochemical Pharmacology. 71(1-2). 69–73. 16 indexed citations
18.
Gupte, Amol & John K. Buolamwini. (2004). Novel halogenated nitrobenzylthioinosine analogs as es nucleoside transporter inhibitors. Bioorganic & Medicinal Chemistry Letters. 14(9). 2257–2260. 16 indexed citations
19.
Buolamwini, John K. & Haregewein Assefa. (2003). Overview of Novel Anticancer Drug Targets. Humana Press eBooks. 85. 3–28. 1 indexed citations
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Daniel Zaharevitz Breakdown of academic impact, for papers by A. Chaikuad Breakdown of academic impact, for papers by Daniel Martinez Molina Breakdown of academic impact, for papers by Thomas O’Brien Breakdown of academic impact, for papers by Jacqueline Plowman Breakdown of academic impact, for papers by Daniel A. Bachovchin Breakdown of academic impact, for papers by Fabrizio Giordanetto Breakdown of academic impact, for papers by Masami Otsuka Breakdown of academic impact, for papers by Haiying Chen Breakdown of academic impact, for papers by Rozbeh Jafari
Rankless by CCL
2026